Prediction of pharmacokinetic alterations caused by drug-drug interactions: Metabolic interaction in the liver

Pharmacological Reviews

Volumn 50, Issue 3, 1998, Pages 387-411

  Ito, K ^a   Iwatsubo, T ^a   Kanamitsu, S ^a   Ueda, K ^a   Suzuki, H ^a   Sugiyama, Yuchi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; DRUG;

BINDING SITE; COMPETITIVE INHIBITION; DRUG METABOLISM; DRUG PROTEIN BINDING; HUMAN; LIVER METABOLISM; PRIORITY JOURNAL; REVIEW;

ANIMALS; AREA UNDER CURVE; CYTOCHROME P-450 ENZYME SYSTEM; DRUG ADMINISTRATION ROUTES; DRUG INTERACTIONS; HUMANS; LIVER; MODELS, BIOLOGICAL; PHARMACOKINETICS;

EID: 0031723235     PISSN: 00316997     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (93)

1. Aronoff GR, Bergstrom RF, Pottratz ST, Sloan RS, Wolen RL and Lemberger L (1984) Fluoxetine kinetics and protein binding in normal and impaired renal function. Clin Pharmacol Ther 36:138-144.
2. Back DJ, Tjia JF, Karbwang J and Colbert J (1988) In vitro inhibition studies of tolbutamide hydroxylase activity of human liver microsomes by azoles, sulfonamides and quinolines. Br J Clin Pharmacol 26:23-29.
3. Benet LZ (1995) Interspecies scaling: New lessons utilizing metabolic isozymes and pharmacokinetics, in International Symposium on Strategy of Drug Metabolism Study for New Drug Development, Tokyo, Japan, June 13-15. pp 43-46.
4. Benet LZ (1996) Problems and progress: From Bio-International '89 to the present, in FIP Bio-International '96, Tokyo, Japan, April 22-24. pp 9-13.
5. Bergstrom RF, Peyton AL and Lemberger L (1992) Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction. Clin Pharmacol Ther 51:239-248.
6. Bertz RJ and Granneman GR (1997) Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 32:210-258.
7. Chiba M, Nishime JA and Lin JH (1995) Potent and selective inactivation of human liver microsomal cytochrome P-450 isoforms by L-754,394, an investigational human immune deficiency virus protease inhibitor. J Pharmacol Exp Ther 275:1527-1534.
8. Christensen LK, Hansen JM and Kristensen M (1963) Sulphaphenazole-induced hypoglycaemic attacks in tolbutamide-treated diabetics. Lancet 2:1298-1301.
9. Daneshmend TK, Warnock DW, Ene MD, Johnson EM, Potten MR, Richardson MD and Williamson PJ (1984) Influence of food on the pharmacokinetics of ketoconazole. Antimicrob Agents Chemother 25:1-3.
10. Daneshmend TK, Warnock DW, Turner A and Roberts CJC (1981) Pharmacokinetics of ketoconazole in normal subjects. J Antimicrob Chemother 8:299-304.
11. Desgranges C, Razaka G, De Clercq E, Herdewijn P, Balzarini J, Drouillet F and Bricaud H (1986) Effect of (E)-5-(2-Bromovinyl)uracil on the catabolism and anti-tumor activity of 5-fluorouracil in rats and leukemic mice. Cancer Res 46:1094-1101.
12. de Waziers I, Cugnenc PH, Yang CS, Leroux J-P and Beaune PH (1990) Cytochrome P450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues. J Pharmacol Exp Ther 253:387-394.
13. Garteiz DA, Hook RH, Walker BJ and Okerholm RA (1982) Pharmacokinetics and biotransformation studies of terfenadine in man. Arzneim-Forsch 32:1185-1190.
14. Gomez DY, Wacher VJ, Tomlanovich SJ, Hebert MF and Benet LZ (1995) The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin Pharmacol Ther 58:15-19.
15. Guay DRP, Awni WM, Peterson PK, Obaid S, Breitenbucher R and Matzke GR (1987) Pharmacokinetics of ciprofioxacin in acutely ill and convalescent elderly patients. Am J Med 82:124-129.
16. Gupta SK, Bakran A, Johnson RWG and Rowland M (1989) Cyclosporinerythromycin interaction in renal transplant patients. Br J Clin Pharmacol 27:475-481.
17. Hebert MF, Roberts JP, Prueksaritanont T and Benet LZ (1992) Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin Pharmacol Ther 52:453-457.
18. Honig PK, Woosley RL, Zamani K, Conner DP and Cantilena LR Jr (1992) Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clin Pharmacol Ther 52:231-238.
19. Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC and Cantilena LR (1993) Terfenadine-ketoconazole interaction. JAMA 269:1513-1518.
20. Hori R, Takano M, Okano T, Kitazawa S and Inui K (1982) Mechanisms of p-aminohippurate transport by brush-border and basolateral membrane vesicles isolated from rat kidney cortex. Biochim Biophys Acta 692:97-100.
21. Hunter WC (1951) Oral administration of procaine penicillin with and without benemid p-(di-n-propylsulphanyl) benzoic acid. Lancet 261:105.
22. Ito K, Iwatsubo T, Kanamitsu S, Nakajima Y and Sugiyama Y (1998) Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism together with binding and transport. Anna Rev Pharmacol Toxicol, 38:461-499.
23. Iwatsubo T, Hirota N, Ooie T, Suzuki H, Shimada N, Chiba K, Ishizaki T, Green CE, Tyson CA and Sugiyama Y (1997) Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol Ther 73:147-171.
24. Iwatsubo T, Hirota N, Ooie T, Suzuki H and Sugiyama Y (1996) Prediction of in vivo drug disposition from in vitro data based on physiological pharmacokinetics. Biopharm Drug Dispos 17:273-310.
25. Jurima-Romet M, Crawford K, Cyr T and Inaba T (1994) Terfenadine metabolism in human liver: In vitro inhibition by macrolide antibiotics and azole antifungals. Drug Metab Dispos 22:849-857.
26. Jurima-Romet M, Huang HS, Beck DJ and Li AP (1996) Evaluation of drug interactions in intact hepatocytes: Inhibitors of terfenadine metabolism. Toxicol In Vitro 10:655-663.
27. Kalow W and Tang BK (1991) Use of caffeine metabolite ratios to explore CYP1A2 and xanthine oxidase activities. Clin Pharmacol Ther 50:508-519.
28. Knodell RG, Browne DG, Gwozdz GP, Brian WR and Guengerich FP (1991) Differential inhibition of individual human liver cytochromes P-450 by cimetidine. Gastroenterology 101:1680-1691.
29. Kolars JC, Awni WM, Merion RM and Watkins PB (1991) First-pass metabolism of cyclosporin by the gut. Lancet 338:1488-1490.
30. Kolars JC, Schmiedlin-Ren P, Schuetz JD, Fang C and Watkins PB (1992) Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest 90:1871-1878.
31. Kunze KL and Trager WF (1993) Isoform-selective mechanism-based inhibition of human cytochrome P450 1A2 by furafylline. Chem Res Toxicol 6:649-656.
32. Kusuhara H, Suzuki H and Sugiyama Y (1998) The role of p-glycoprotein and canalicular multispecific organic anion transporter (cMOAT) in the hepatobiliary excretion of drugs. J Pharm Sci, in press.
33. Lensmeyer GL, Wiebe DA and Carlson IH (1988) Deposition of nine metabolites of cyclosporine in human tissues, bile, urine, and whole blood. Transplant Proc 20:614-622.
34. Li AP and Jurima-Romet M (1997) Applications of primary human hepatocytea in the evaluation of pharmacokinetic drug-drug interactions: Evaluation of model drugs terfenadine and rifampin. Cell Biol Toxicol 13:365-374.
35. Miller LG, Prichrd JG, White CA, Vytla B, Feldman S and Bowman RC (1990) Effect of concurrent sucralfate administration on the absorption of erythromycin. J Clin Pharmacol 30:39-44.
36. Miners JO, Smith KJ, Robson RA, McManua ME, Veronese ME and Birkett DJ (1988) Tolbutamide hydroxylation by human liver microsomes. Biochem Pharma. col 37:1137-1144.
37. Monahan BP, Ferguson CL, Killeavy ES, Lloyd BK, Troy J and Cantilena LR (1990) Torsades de pointes occurring in association with terfenadine use. JAMA 264:2788-2790.
38. Murray M and Reidy GF (1990) Selectivity in the inhibition of mammalian cytochromes P-450 by chemical agents. Pharmacol Rev 42:85-101.
39. 2 receptor antagonists, cimetidine and nizatidine, into isolated rat hepatocytes: Contribution of Type 1 system. J Pharmacol Exp Ther 269:1220-1227.
40. Nelson E and O'Reilly I (1961) Kinetics of carboxytolbutamide excretion following tolbutamide and carboxytolbutamide administration. J Pharmacol Exp Ther 132:103-109.
41. Oberle RL, Chen T-S, Lloyd C, Barnett JL, Owyang C, Meyer J and Amidon GL (1990) The influence of the interdigestive migrating myoelectric complex on the gastric emptying of liquids. Gastroenterology 99:1275-1282.
42. Okuda H, Nishiyama T, Ogura K, Nagayama S, Ikeda K, Yamaguchi S, Nakamura Y, Kawaguchi Y and Watabe T (1995) Mechanism of lethal toxicity exerted by simultaneous administration of the new antiviral, sorivudine, and the antitumor agent, Tegafur, Xenobio Metabol Dispos 10(Suppl):166-169.
43. Okuda H, Nishiyama T, Ogura K, Nagayama S, Ikeda K, Yamaguchi S, Nakamura Y, Kawaguchi Y and Watabe T (1997) Lethal drug interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs. Drug Metab Dispos 25:270-273.
44. Parkinson A (1996) Biotransforraation of xenobiotics, in Casarett & Doull's Toxicology: The Basic Science of Poisons (Klaassen CD ed) ed 5, pp 113-186, McGraw-Hill, New York.
45. Periti P, Mazzei T, Mini E and Novelli A (1992) Pharmacokinetic drug interactions of macrolides. Clin Pharmacokinet 23:106-131.
46. Pharmaceutical Affairs Bureau, Japanese Ministry of Health and Welfare (1994) A report on investigation of side effects of sorivudine: Deaths caused by interactions between sorivudine and 5-FU prodrugs (in Japanese). June, 1994.
47. Pichard L, Fabre I, Fabre G, Domergue J, Saint Aubert B, Mourad G and Maurel P (1990) Cyclosporin A drug interactions: Screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. Drug Metab Dispos 18:595-605.
48. Preskorn SH, Beber JH, Faul JC and Hirschfeld RMA (1990) Serious adverse effects of combining fluoxetine and tricyclic antidepressants [letter]. Am J Psychiatry 147:532.
49. Rolan PE (1994) Plasma protein binding displacement interactions-why are they still regarded as clinically important? Br J Clin Pharmacol 37:125-128.
50. Rowland M and Martin SB (1973) Kinetics of drug-drug interactions. J Pharmacokinet Biopharm 1:553-567.
51. Rowland M and Tozer TN (1995) Interacting drugs, in Clinical Pharmacokinetics: Concepts and Applications (Rowland M and Tozer TN eds) pp 267-289, Williams & Wilkins, Philadelphia.
52. Saitoh H and Aungst BJ (1995) Possible involvement of multiple P-glycoproteinmediated efflux systems in the transport of verapamil and other organic cations across rat intestine. Pharmaceut Res 12:1304-1310.
53. Sasabe H, Terasaki T, Tsuji A and Sugiyama Y (1997) Carrier-mediated hepatic uptake of quinolone antibiotics in the rat. J Pharmacol Exp Ther 282:162-171.
54. Sathirakul K, Suzuki H, Yamada T, Hanano M and Sugiyama Y (1994) Multiple transport systems for organic anions across the bile canalicular membrane. J Pharmacol Exp Ther 268:65-73.
55. Schellens JHM, Ghabrial H, van der Wart HHF, Bakker EN, Wilkinson GR and Breimer DD (1991) Differential effects of quinidine on the disposition of nifedipine, sparteine, and mephenytoin in humans. Clin Pharmacol Ther 50:520-528.
56. Schuetz EG, Beck WT and Schuetz JD (1996) Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol 49:311-318.
57. Shimamura H, Suzuki H, Hanano M, Suzuki A, Tagaya O, Horie T and Sugiyama Y (1994) Multiple systems for the biliary excretion of organic anions in rats: Liquiritigenin conjugates as model compounds. J Pharmacol Exp Ther 271:370-378.
58. Shimamura H, Suzuki H, Tagaya O, Horie T and Sugiyama Y (1996) Biliary excretion of glucyrrhizin in rats: Kinetic basis for multiplicity in bile canalicular transport of organic anions. Pharmaceut Res 13:1833-1837.
59. Silverman RB (1988) Mechanism-based enzyme inactivation, in Chemistry and Enzymology, vol 1, pp 3-30, CRC Press, Boca Raton.
60. Skjelbo E and Brosen K (1992) Inhibitors of imipramine metabolism by human liver microsomes. Br J Clin Pharmacol 34:256-261.
61. Slater LM, Sweet P, Stupeckey M and Gupta S (1986) Cyclosporin A reverses vincristine and daunorubicin resistance in acute lymphatic leukemia in vitro. J Clin Invest 77:1405-1408.
62. Somogyi A and Muirhead M (1987) Pharmacokinetic interactions of cimetidine 1987. Clin Pharmacokinet 12:321-366.
63. Statkevich P, Fournier DJ and Sweeney KR (1993) Characterization of methotrexate elimination and interaction with indomethacin and flurbiprofen in the isolated perfused rat kidney. J Pharmacol Exp Ther 265:1118-1124.
64. Stille W, Harder S, Mieke S, Beer C, Shah PM, Frech K and Staib AH (1987) Decrease of caffeine elimination in man during co-administration of 4-quinolones. J Antimicrob Chemother 20:729-734.
65. Sugita O, Sawada Y, Sugiyama Y, Iga T and Hanano M (1981) Prediction of drug-drug interaction from in vitro plasma protein binding and metabolism. Biochem Pharmacol 30:3347-3354.
66. Sugita O, Sawada Y, Sugiyama Y, Iga T and Hanano M (1984) Kinetic analysis of tolbutamide-sulfonamide interaction in rabbits based on clearance concept: Prediction of species difference from in vitro plasma protein binding and metabolism. Drug Metab Dispos 12:131-138.
67. Sugiyama Y and Iwatsubo T (1996) Alteration of pharmacokinetic features caused by drug interactions. Xenobio Metabol Dispos 11:286-293.
68. Sugiyama Y, Iwatsubo T, Ueda K and Ito K (1996) Strategic proposals for avoiding toxic interactions with drugs for clinical use during development and after marketing of a new drug pharmacokinetic consideration. J Toxicol Sci 21:309-316.
69. Sugiyama Y and Ooie T (1993) Prediction of pharmacokinetics based on in vitro data, in Methods and Techniques for Pharmacokinetic Studies (Sugiyama Y ed) pp 87-108, Japanese Society for the Study of Xenobiotics, Tokyo.
70. Takano M, Inui K, Okano T, Saitoh H and Hori R (1984) Carrier-mediated transport systems of tetraethylammonium in rat brush-border and basolateral membrane vesicles. Biochim Biophys Acta 773:113-124.
71. Tanigawara Y, Okumura N, Hirai M, Yasuhara M, Ueda K, Kioka N, Komano T and Hori R (1992) Transport of digoxin by human p-glycoprotein expressed in a porcine kidney epithelial cell line (LLC-PK1). J Pharmacol Exp Ther 263:840-845.
72. Terao T, Hisanaga E, Sai Y, Tamai I and Tsuji A (1996) Active secretion of drugs from the small intestinal epithelium in rats by P-glycoprotein functioning as an absorption barrier. J Pharm Pharmacol 48:1083-1089.
73. Thomas RC and Ikeda GJ (1966) The metabolic fate of tolbutamide in man and in the rat. J Med Chem 9:507-510.
74. Thummel KE, O'Shea D, Paine MF, Shen DD, Kunze KL, Perkins JD and Wilkinson GR (1996) Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther 59:491-502.
75. Todhunter JA (1979) Reversible enzyme inhibition, in Methods in Enzymology (Purich DL ed) vol 63, pp 383-411, Academic Press, London.
76. Transon C, Leemann T and Dayer P (1996) In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors. Eur J Clin Pharmacol 50:209-215.
77. Tsuruo T, lida H, Tsukagoshi S and Sakurai Y (1981) Overcoming of vincristine resistance in P388 leukemia, in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 41:1967-1972.
78. Tucker GT (1992) The rational selection of drug interaction studies: Implications of recent advances in drug metabolism. Int J Clin Pharmacol Ther Toxicol 30:550-553.
79. Vereerstraeten P, Thiry P, Kinnaert P and Toussaint C (1987) Influence of erythromycin on cyclosporine pharmacokinetics. Transplantation 44:155-156.
80. Veronese ME, Miners JO, Randles D, Gregov D and Birkett DJ (1990) Validation of the tolbutamide metabolic ratio for population screening with use of sulfaphenazole to produce model phenotypic poor metabolizers. Clin Pharmacol Ther 47:403-411.
81. von Moltke LL, Greenblatt DJ, Duan SX, Harmatz JS and Shader RI (1994) In vitro prediction of the terfenadine-ketoconazole pharmacokinetic interaction. J Clin Pharmacol 34:1222-1227.
82. von Moltke LL, Greenblatt DJ, Harmatz JS, Duan SX, Harrel LM, Cotreau-Bibbo MM, Pritchard GA, Wright CE and Shader RI (1996) Triazolam biotransformation by human liver microsomes in vitro: Effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. J Pharmacol Exp Ther 276:370-379.
83. Wacher VJ, Wu C-Y and Benet LZ (1995) Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: Implications for drug delivery and activity in cancer chemotherapy. Mol Careinog 13:129-134.
84. Wagner F, Kalusche D, Trenk D, Jahnchen E and Roskamm H (1987) Drug interaction between propafenone and metoprolol. Br J Clin Pharmacol 24:213-220.
85. Waley SG (1985) Kinetics of suicide substrates: Practical procedures for determining parameters. Biochem J 227:843-849.
86. Watabe T (1996) Strategic proposals for predicting drug-drug interactions during new drug development: Based on sixteen deaths caused by interactions of the new antiviral sorivudine with 5-fluorouracil prodrugs. J Toxicol Sci 21:299-300.
87. Wilkinson GR (1983) Plasma and tissue binding considerations in drug disposition. Drug Metab Rev 14:427-465.
88. Wu C-Y, Benet LZ, Heben MF, Gupta SK, Rowland M, Gomez DY and Wacher VJ (1995) Differentiation of absorption and first-pass gut and hepatic metabolism in humans: Studies with cyclosporine. Clin Pharmacol Ther 58:492-497.
89. Yamada T, Niinuma K, Lemaire M, Terasaki T and Sugiyama Y (1997) Carriermediated hepatic uptake of the cationic cyclopeptide, octreotide, in rats: Comparison between in vivo and in vitro. Drug Metab Dispos 25:536-543.
90. Yamazaki M, Nishigaki R, Suzuki H and Sugiyama Y (1995) Kinetic analysis of hepatobiliary transport of drugs: Importance of carrier-mediated transport. Yakugaku Zasshi 115:953-977.
91. +-independent multispecific anion transporter mediates active transport of pravastatin into rat liver. Am J Physiol 264:G36-G44.
92. Yamazaki M, Suzuki H and Sugiyama Y (1996) Recent advances in carrier-mediated hepatic uptake and biliary excretion of xenobiotics. Pharmaceut Res 13:497-513.
93. Zomorodi K and Houston JB (1995) Effect of omeprazole on diazepam disposition in the rat: In vitro and in vivo studies. Pharmaceut Res 12:1642-1646.